| 引用本文：丁锦希, 董锐, 李伟, 龚博君, 王君焱.我国药品集中采购制度“竞价分组”政策的评价与思考——基于2016年各省集中采购方案的统计分析[J].中国卫生政策研究,2016,9(9):52-59 |
|
| 我国药品集中采购制度“竞价分组”政策的评价与思考——基于2016年各省集中采购方案的统计分析 |
| 投稿时间：2016-06-29 修订日期：2016-09-06 PDF全文浏览 HTML全文浏览 |
| 丁锦希1, 董锐1, 李伟1, 龚博君2, 王君焱1 |
1. 中国药科大学国际医药商学院 江苏南京 211198;
2. 华润赛科药业有限责任公司 北京 100124 |
| 摘要:2015年，国家相继出台药品集中采购制度改革文件，将药品质量作为改革的重点内容。药品集中采购制度主要利用竞价分组区分药品质量层次，达到“质量优先”的目的。但现阶段我国竞价分组存在层级划分不统一、指标构建不科学等问题，弱化了集中采购对药品质量的引导作用。本文以竞价分组作为研究对象，通过对各省（市）最新出台的采购文件中有关竞价分组的相关内容进行统计分析，发现竞价分组存在的主要问题，在此基础上探索我国竞价分组完善和优化的策略。 |
| 关键词:药品集中采购 竞价分组 政策评价 |
| 基金项目:2015年与2016年国家卫生与计划生育委员会委托课题（药政[2015] 12号；药政[2016]11号） |
|
| Assessment and rational thinking of “Bidding Group” in Chinese centralized drug procurement system |
| DING Jin-xi1, DONG Rui1, LI Wei1, GONG Bo-jun2, WANG Jun-yan1 |
1. School of Pharmaceutical Business of China Pharmaceutical University, Nanjing Jiangsu 211198, China;
2. China Resources Saike Pharmaceutical Co., Ltd, Beijing 100124, China |
| Abstract:In 2015, policy reforms on centralized drug purchasing system have been released one by one, and the quality of medicines has been highly valued. Centralized drug purchasing system distinguishes different qualities of drugs mainly through bidding grouping, in order to achieve "uality priority". However, there are yet some existing problems in group bidding policy at present, such as lack of a unified hierarchy, no scientific indicators and so on, which inevitably weaken the leading role of centralized purchasing policy over the quality of medicines. This paper, focuses on the study of group bidding, and the existing main problems are found through the statistical analysis of relevant policies introduced in different provinces. Finally, it explores some optimization strategies for "Group Bidding" which is of paramount importance. |
| Key words:Centralized drug procurement Bidding group Policy evaluation |
| 摘要点击次数: 2153 全文下载次数: 2143 |
|
|
|
|
|
